Company Overview of Cell>Point L.L.C.
Cell>Point L.L.C., a biopharmaceutical company, develops intra-nuclear universal molecular imaging and therapeutic products for the diagnosis, staging, treatment, and post therapy assessment of cancer, cardiovascular diseases, and infectious diseases. The company focuses on developing universal oncology, cardiology, stroke and diabetes molecular imaging agents, and intra-nuclear metallic therapeutics. It offers radiodiagnostic imaging and intra-nuclear therapeutic agents, and delivery systems for the administration of local regional radio/chemotherapy. The company also provides 99mTc-EC-G (oncology), a metabolic imaging agent used to diagnose hyper metabolic activity in cancer cells; 99mTc-E...
7120 East Orchard Road
Centennial, CO 80111
Founded in 2001
Key Executives for Cell>Point L.L.C.
Chief Executive Officer, Founding Member, Managing Member and Founder
Founder, Founding Member, Managing Member and Chief Financial Officer
Founder, Managing Partner, Founding Member and Chief Technology Officer
Compensation as of Fiscal Year 2014.
Cell>Point L.L.C. Key Developments
Cell>Point L.L.C. Announces Encouraging Results from (99m) Tc--EC--G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease
Apr 9 13
Cell>Point L.L.C. announced results from conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri. The study imaged patients with technetium-99m-labeled EthylenediCysteine-Glucosamine (99mTc-EC-G), Cell>Point's proprietary nuclear imaging product candidate, which is target specific for detecting the presence and extent of ischemia in patients with Coronary Artery Disease (CAD). The results from the Phase 1 and 2a studies show that 99mTc-EC-G has the potential to accurately diagnose myocardial ischemia (that is, decrease in blood flow and oxygen to heart muscle) in as little as 30 minutes post injection in patients studied at rest only. The multicenter Phase 2b trial will evaluate the diagnostic accuracy (sensitivity and specificity) of a 99mTc-EC-G study performed at rest only compared to a two-day 99mTc-Cardiolite rest/stress study to determine the presence, anatomical location, and severity of ischemia in patients with CAD. Diagnostic catheterization will be used as the standard of truth. Camargo Pharmaceutical Services of Cincinnati will perform the role of general manager over the clinical research and regulatory function for the study. Premier Research of Research Triangle Park, North Carolina, will continue their role as the clinical research organization for the study.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries